vVARDIS Holding AG, a Zug-based dental medtech company pioneering non-invasive cavity treatment, attracted a strategic minority investment from Apollo-managed funds. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs.

vVARDIS控股公司是一家位于楚格的牙科医疗技术公司，致力于非侵入性龋齿治疗，吸引了由阿波罗管理的基金的战略性少数投资。这项投资使vVARDIS成为欧洲少数几家私有且价值超过十亿美元的医疗保健公司之一。vVARDIS的创始人兼联合首席执行官为博士。

Haley and Goly Abivardi, will retain a substantial majority shareholding in the company..

海莉和戈利·阿比瓦迪将保留公司的绝大部分股权。

vVARDIS is redefining the treatment of cavities through its Curodont technology, the first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. Curodont supports enamel repair by facilitating the formation of crystalline mineral structure throughout the affected area, giving dental professionals an easy-to-use, restorative option to treat early-stage cavities as an alternative to traditional drilling..

vVARDIS正在通过其Curodont技术重新定义龋齿的治疗方法，这是首个也是唯一一个商用的、含肽的非侵入性配方，临床证明可以治疗蛀牙。Curodont通过促进整个患处结晶矿物结构的形成来支持牙釉质修复，为牙科医生提供了一种易于使用的修复选项，用于治疗早期龋齿，作为传统钻孔的替代方案。

Backed by 25 years of research and more than 10 years of use in clinical practices globally, vVARDIS’ products and science are supported by more than 250 scientific publications, including meta-analysis, peer-reviewed and long-term peer-reviewed real-world evidence clinical studies, with a documented success rate above 90%..

凭借25年的研究和全球临床实践中超过10年的应用，vVARDIS的产品和科学得到了250多篇科学出版物的支持，包括荟萃分析、同行评审以及长期同行评审的真实世界证据临床研究，其记录的成功率超过90%。

Tooth decay is the world’s most prevalent non-communicable disease, affecting nearly 90 percent of US adults. vVARDIS’ targets an addressable market of over $30 billion in the US.

龋齿是世界上最普遍的非传染性疾病，影响了近90%的美国成年人。vVARDIS的目标市场在美国超过300亿美元。

Since the launch of Curodont Repair Fluoride Plus in the U.S. over two years ago, it has been used to treat approximately 3 million teeth, is now present in nearly 20 percent of general dental practices nationwide and is one of the fastest-growing dental products in the U.S.

自从两年前Curodont Repair Fluoride Plus在美国推出以来，它已经被用于治疗大约300万颗牙齿，现在在全国近20%的普通牙科诊所中使用，并且是美国增长最快的牙科产品之一。

The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont suite of products. The financial terms of the transaction were not disclosed.

这项投资将支持vVARDIS下一阶段的全球增长和商业扩展，包括继续推出其Curodont系列产品。本次交易的财务条款未披露。

“vVARDIS has built a differentiated business, with Drs. Haley and Goly Abivardi pioneering a new category in dental care backed by peer-reviewed clinical studies,” said Jeremy Honeth, Partner and Andrea Vanni, Managing Director at Apollo. “Apollo Funds’ investment supports the company’s continued expansion in key markets across the US and Europe, bringing this restorative therapy to more practices and patients worldwide.” Apollo is a high-growth, global alternative asset manager.

“vVARDIS 开创了差异化的业务，Haley 博士和 Goly Abivardi 博士通过同行评审的临床研究开创了牙科护理的新领域，”阿波罗合伙人 Jeremy Honeth 和董事总经理 Andrea Vanni 表示。“阿波罗基金的投资支持了该公司在美国和欧洲主要市场的持续扩张，将这种修复疗法带给全球更多的诊所和患者。” 阿波罗是一家高增长的全球另类资产管理公司。

As of December 31, 2025, Apollo had approximately $938 billion of assets under management. .

截至2025年12月31日，阿波罗管理的资产约为9380亿美元。

“Curodont fills a longstanding gap in dentistry: when prevention fails, dentists now have a quick, easy-to-use non-invasive treatment free of drilling and needles. The rapid adoption of Curodont reflects the urgency of that unmet need,” said Haley Abivardi, DMD, co-CEO and co-founder of vVARDIS. “Apollo Funds’ investment strengthens our commercial foundation in the US and Europe and enables us to scale this environmentally sustainable technology across markets.”.

“Curodont 填补了牙科领域长期以来的一个空白：当预防措施失败时，牙医现在拥有了一种快速、易于使用且无需钻孔和注射的非侵入性治疗方法。Curodont 的迅速普及反映了这一未满足需求的紧迫性，”vVARDIS 的联合首席执行官兼联合创始人 Haley Abivardi 医学博士表示。“阿波罗基金的投资巩固了我们在美国和欧洲的商业基础，并使我们能够将这项环保可持续的技术推广到各个市场。”

Goly Abivardi, DMD, co-CEO and co-founder of vVARDIS, said, “Our mission is to bring a medical, science driven approach to dentistry. Using peptide-containing formulations, our non-invasive technology is an innovative treatment designed to treat tooth decay without drilling and without polymer materials.

vVARDIS 的联合首席执行官兼联合创始人戈利·阿比瓦迪 (Goly Abivardi) 表示：“我们的使命是将医学和科学驱动的方法引入牙科领域。我们利用含肽配方的非侵入性技术是一种创新疗法，旨在无需钻孔和聚合物材料的情况下治疗蛀牙。”

Apollo Funds’ investment reinforces our leadership in generative dentistry and advances the future of oral science.”.

阿波罗基金的投资巩固了我们在生成性牙科学领域的领导地位，并推动了口腔科学的未来发展。

(Press release / SK)

（新闻稿 / SK）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送